Trials / Terminated
TerminatedNCT04855565
ALY688-SR in Generally Healthy Overweight or Obese Adults
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of ALY688-SR in Generally Healthy Overweight or Obese Adults
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Allysta Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
First in human study of ALY688-SR administered as a subcutaneous injection
Detailed description
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of ALY688-SR compared to placebo administered as a subcutaneous injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALY688-SR | single dose subcutaneous injection |
Timeline
- Start date
- 2021-05-19
- Primary completion
- 2021-08-03
- Completion
- 2021-08-03
- First posted
- 2021-04-22
- Last updated
- 2021-08-30
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04855565. Inclusion in this directory is not an endorsement.